Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Zhengye Biotechnology Holding's Revenue for the
six
months ended in Dec. 2025 was $7.67 Mil. Zhengye Biotechnology Holding's average Accounts Receivable for the
six
months ended in Dec. 2025 was $3.88 Mil.
Hence, Zhengye Biotechnology Holding's Receivables Turnover for the
six
months ended in Dec. 2025 was 1.98.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Zhengye Biotechnology Holding Receivables Turnover Related Terms
Zhengye Biotechnology Holding Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZYBT vs TLPH, CPHI, CPIX: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zhengye Biotechnology Holding's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhengye Biotechnology Holding Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhengye Biotechnology Holding's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Zhengye Biotechnology Holding's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhengye Biotechnology Holding (ZYBT) has a Receivables Turnover of 1.98 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Zhengye Biotechnology Holding and its competitors. According to the industry distribution chart, Zhengye Biotechnology Holding ranks #771 out of 946 companies in the Drug Manufacturers industry, placing it in the top 81.5%.
Is Zhengye Biotechnology Holding's Receivables Turnover too high?
Zhengye Biotechnology Holding's current Receivables Turnover is 1.98. The Drug Manufacturers industry median Receivables Turnover is 5.09. Zhengye Biotechnology Holding's value of 1.98 is 61.1% below this industry median. Based on the distribution chart, Zhengye Biotechnology Holding ranks #771 out of 946 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zhengye Biotechnology Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Zhengye Biotechnology Holding's Receivables Turnover compare to TLPH and CPHI?
According to the Drug Manufacturers industry distribution chart, Zhengye Biotechnology Holding ranks #771 out of 946 companies for Receivables Turnover. This places Zhengye Biotechnology Holding in the lower half of its industry. The industry median Receivables Turnover is 5.09. Zhengye Biotechnology Holding's value of 1.98 is 61.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.09, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhengye Biotechnology Holding's current Receivables Turnover of 1.98 is 61.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Zhengye Biotechnology Holding and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhengye Biotechnology Holding's current Receivables Turnover is 1.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhengye Biotechnology Holding stock overvalued right now?
Zhengye Biotechnology Holding (ZYBT) has a current Receivables Turnover of 1.98. The current Receivables Turnover is 1.98 and 61.1% below the Drug Manufacturers industry median of 5.09. Zhengye Biotechnology Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Zhengye Biotechnology Holding (ZYBT), the current Receivables Turnover is 1.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry and other vaccines.
20GF Score
Get the complete analysis for ZYBT
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZYBT has been successfully added to your 
